Australia News

Found 7,330 articles

• PYC Therapeutics Highlights Advancement of Ocular and CNS Development Programs And Continued U.S. Expansion in Second Quarter 2021 Update

  7/28/2021

  PYC Therapeutics, a biotechnology company combining two complementary platform technologies to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, announced a second quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.

• atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs

  7/28/2021

  atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc.

• Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

  7/28/2021

  Clarity Pharmaceuticals, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient recruitment has commenced with the opening of the first clinical site at the Urology Cancer Center and GU Research Network in Omaha, Nebraska.

• US Patent Office issues Notice of Allowance status for NRGBiotic™ for treating, preventing, or Ameliorating depression or a Depressive disorder.

  7/27/2021

  Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is very pleased to announce the United States Patent Office (USPTO) has issued a Notice of Allowance for Application number 15/523,271 for the formulation known as NRGBiotic™, currently available in Australian Pharmacies.

• Genetic Technologies Rapidly Accelerating Commercialization Plans

  7/26/2021

  Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market.

• SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis

  7/26/2021

  SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern.

• Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives

  7/22/2021

  Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the United States (U.S.) Patent and Trademark Office has granted Patent Family 3 “Anti-Virus Agent and Method for Treatment Of Viral Infections,” furthering marketing and manufacturing monopolies to February 2037.

• Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives

  7/21/2021

  Recce Pharmaceuticals Ltd is pleased to announce the Chinese Patent Office has granted Patent Family 3 “ Anti-Virus Agent and Method for Treatment Of Viral Infections ”

• Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

  7/21/2021

  Kazia Therapeutics Limited, a leading drug development company in the field of brain cancer, recognizes Glioblastoma Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.

• Omniscient Neurotechnology Launches Quicktome™ Brain Mapping Platform for Neurosurgery After Regulatory Clearance in United States, Canada and Australia

  7/21/2021

  Omniscient Neurotechnology today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Quicktome™, a digital brain mapping platform that allows neurosurgeons to visualize and understand a patient's brain networks prior to performing life-changing brain surgery.

• Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria

  7/20/2021

  RECCE is pleased to announce positive efficacy of RECCE® 327 (R327) against Clostridium perfringens (C. perfringens) and Streptococcus pyogenes (S. pyogenes), two main strains of bacteria associated with necrotizing fasciitis, also known as ‘flesh-eating’ disease – a life-threatening bacterial infection with a mortality rate of up to 80%.

• Brain Mapping Pioneer Omniscient Neurotechnology Raises AUD 40 Million in Series B Financing

  7/19/2021

  Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, today announced the completion of an AUD 40 million Series B financing round.

• Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function

  7/15/2021

  Alterity Therapeutics  today announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces α–synuclein related neurodegeneration in a widely accepted murine model of Multiple System Atrophy (MSA)[1].

• ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

  7/13/2021

  ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has initiated a Phase I human safety study of INNA-051, being developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections.

• CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

  7/13/2021

  Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia .

• Immutep Quarterly Activities Report - July 13, 2021

  7/13/2021

  Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 June 2021.

• Recce Pharmaceuticals Announces Multiple Patients Dosed with RECCE® 327 in Topical Phase I/II Clinical Trial for the Treatment of Infected Burn Wounds

  7/12/2021

  Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), the Company developing new classes of synthetic anti-infectives is pleased to announce multiple patients have been dosed with RECCE® 327 (R327) in a topical Phase I/II clinical trial at the Fiona Stanley Hospital Burns Unit in Perth, Western Australia

• Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multiple Cancers & Morbidities

  7/9/2021

  Genetic Technologies Limited  today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma.

• Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

  7/6/2021

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce that the U.S. Food and Drug Administration has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with neovascular age-related macular degeneration.

• New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

  7/6/2021

  QBiotics Group Limited, an Australian life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce the Australian Pesticides and Veterinary Medicines Authority has approved* its lead veterinary product STELFONTA®.